Indications for ADMELOG:
Type 1 diabetes mellitus in adults and children. Type 2 diabetes mellitus in adults.
Adults and Children:
<3yrs: not established. ≥3yrs: Individualize. For SC inj: give within 15mins before a meal or immediately after a meal; use with intermediate or long-acting insulin. Rotate inj sites (abdomen, thigh, upper arm, buttocks). For continuous SC infusion pump: administer into abdominal wall; do not dilute or mix Admelog; change Admelog in the reservoir at least every 7 days, change the infusion sets and insertion site at least every 3 days. For IV inj: dilute Admelog; give only under medical supervision; closely monitor blood glucose and potassium.
During episodes of hypoglycemia.
Do not share pens between patients, or needles and syringes when using vials. Instruct patients on proper administration of insulin, check insulin label before each injection, and management of hypoglycemia. Increased risk of hypo- or hyperglycemia if changes in physical activity, meal patterns, concomitant medications, renal or hepatic function, insulin regimen and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K+-lowering or K+-sensitive drugs). Discontinue if hypersensitivity reactions occur. Hyperglycemia and ketoacidosis due to insulin pump device malfunction: see full labeling. Renal or hepatic impairment. Pregnancy. Nursing mothers.
Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by oral antidiabetic agents, ACE inhibitors, ARBs, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (eg, octreotide), sulfonamide antibiotics. Antagonized by atypical antipsychotics, corticosteroids, isoniazid, niacin, danazol, diuretics, glucagon, phenothiazines, sympathomimetics, somatropin, thyroid hormones, oral contraceptives, estrogens, protease inhibitors. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Concomitant β-blockers, clonidine, guanethidine, reserpine may blunt hypoglycemia. Do not mix with any other insulin.
Hypoglycemia, allergic reactions, inj site reactions, lipodystrophy, pruritus, rash, hypokalemia, weight gain, peripheral edema; hypersensitivity reactions.
Multi-dose vials (10mL)—1; SoloStar prefilled pen (3mL)—5